Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Moderna Stock Plunged Today

By Joe Tenebruso - Dec 22, 2020 at 6:36PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Coronavirus mutations could undermine the success of the drugmaker's vaccine.

What happened 

Shares of Moderna ( MRNA 1.74% ) fell 9% on Tuesday as the biotech raced to determine if its coronavirus vaccine is effective against a highly contagious new strain of the virus. 

So what

Investors and the world at large cheered when a phase 3 clinical trial showed Moderna's vaccine candidate, mRNA-1273, to be 94% effective against COVID-19 and 100% effective at preventing severe forms of the disease. Moderna's share price went on to nearly double after the drugmaker released data from an interim analysis of the clinical trial in mid-November. 

A downwardly sloping stock chart.

Moderna's stock has pulled back sharply in recent days. Image source: Getty Images.

However, after reaching an all-time high of $178.50 on Dec. 1, Moderna has lost roughly 30% of its value. Investors are growing increasingly concerned about a new strain of the coronavirus that is rapidly spreading throughout the U.K., which has led government officials to impose new lockdown measures and more than 40 other nations to enact travel bans. 

Now what 

Health officials are optimistic that Moderna's vaccine will prove effective against the new virus strain, but it will take time before they can be more certain. Moderna is currently performing tests to confirm its vaccine's efficacy against the new variant of the virus, and it hopes to be able to provide more data in the coming weeks. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$306.72 (1.74%) $5.23

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
624%
 
S&P 500 Returns
140%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/06/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.